J Clin Neurol.  2008 Jun;4(2):84-88. 10.3988/jcn.2008.4.2.84.

Multiplex Analysis of Cytokines in the Serum and Cerebrospinal Fluid of Patients With Alzheimer's Disease by Color-Coded Bead Technology

• Choi C
• Jeong JH
• Jang JS
• Choi K
• Lee J
• Kwon J
• Choi KG
• Lee JS
• Kang SW

• KMID: 2178927
• DOI: http://doi.org/10.3988/jcn.2008.4.2.84

Abstract

Background and purpose
The availability and promise of effective treatments for neurodegenerative disorders are increasing the importance of early diagnosis. Having molecular and biochemical markers of Alzheimer's disease (AD) would complement clinical approaches, and further the goals of early and accurate diagnosis. Combining multiple biomarkers in evaluations significantly increases the sensitivity and specificity of the biochemical tests. Methods: In this study, we used color-coded bead-based Luminex technology to test the potential of using chemokines and cytokines as biochemical markers of AD. We measured the levels of 22 chemokines and cytokines in the serum and cerebrospinal fluid (CSF) of 32 de novo patients (13 controls, 11 AD, and 8 Parkinson's disease [PD]). Results: MCP-1 was the only cytokine detectable in CSF, and its levels did not differ between control and disease groups. However, the serum concentration of eotaxin was significantly higher in AD patients than in the control group. Conclusions: The analysis of multiple inflammatory mediators revealed marginal differences in their CSF and serum concentrations for the differential diagnosis of AD and PD. These results provide evidence that immunological responses are not major contributors to the pathogenesis of AD and PD.

Keyword

Alzheimer's disease; Biomarker; Serum; Cerebrospinal fluid; Neurodegeneration

MeSH Terms

Alzheimer Disease
Biomarkers
Chemokines
Complement System Proteins
Cytokines
Diagnosis, Differential
Early Diagnosis
Humans
Neurodegenerative Diseases
Parkinson Disease
Sensitivity and Specificity
Chemokines
Complement System Proteins
Cytokines

Reference

1. Vellas B, Andrieu S, Sampaio C, Wilcock G. European Task Force group. Disease-modifying trials in Alzheimer's disease: a European task force consensus. Lancet Neurol. 2007. 6:56–62.

2. Mayeux R. Evaluation and use of diagnostic tests in Alzheimer's disease. Neurobiol Aging. 1998. 19:139–143.

3. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the The National Institute on Aging Working Group. Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". Neurobiol Aging. 1998. 19:109–116.

4. Kahle PJ, Jakowec M, Teipel SJ, Hampel H, Petzinger GM, Di Monte DA, et al. Combined assessment of tau and neuronal thread protein in Alzheimer's disease CSF. Neurology. 2000. 54:1498–1504.

5. Olsson A, Vanderstichele H, Andreasen N, De Meyer G, Wallin A, Holmberg B, et al. Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau(Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem. 2005. 51:336–345.

6. Ryu W, Choi C. Application of proteomics and protein chip analysis in the diagnosis of neurodegenerative disorders. J Korean Neurol Assoc. 2003. 21:584–599.

7. Lee ST, Jung KH, Lee YS. Decreased vasomotor reactivity in Alzheimer's Disease. J Clin Neurol. 2007. 3:18–23.

8. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry. 1988. 51:745–752.

9. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984. 34:939–944.

10. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid (42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007. 64:343–349.

11. Davidsson P, Sjogren M. The use of proteomics in biomarker discovery in neurodegenerative diseases. Dis Markers. 2005. 21:81–92.

12. Galimberti D, Schoonenboom N, Scarpini E, Scheltens P. Dutch-Italian Alzheimer Research Group. Chemokines in serum and cerebrospinal fluid of Alzheimer's disease patients. Ann Neurol. 2003. 53:547–548.

13. Economou E, Tousoulis D, Katinioti A, Stefanadis C, Trikas A, Pitsavos C, et al. Chemokines in patients with ischaemic heart disease and the effect of coronary angioplasty. Int J Cardiol. 2001. 80:55–60.

14. Vasudevan AR, Wu H, Xydakis AM, Jones PH, Smith EO, Sweeney JF, et al. Eotaxin and obesity. J Clin Endocrinol Metab. 2006. 91:256–261.

15. Jensen J, Krakauer M, Sellebjerg F. Cytokines and adhesion molecules in multiple sclerosis patients treated with interferon-beta1b. Cytokine. 2005. 29:24–30.

16. Weijer S, Florquin S, van der Poll T. Endogenous interleukin-12 improves the early antimicrobial host response to murine Escherichia coli peritonitis. Shock. 2005. 23:54–58.

17. Mollenhauer B, Trenkwalder C, von Ahsen N, Bibl M, Steinacker P, Brechlin P, et al. Beta-amlyoid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia. Dement Geriatr Cogn Disord. 2006. 22:200–208.

18. Holmberg B, Johnels B, Blennow K, Rosengren L. Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy. Mov Disord. 2003. 18:186–190.